Liquidia to Present Four ASCENT Study Posters on YUTREPIA Data at PHA Conference
LQDA•Liquidia will present four posters on its ASCENT study of YUTREPIA (treprostinil) inhalation powder at the PHA 2026 PH Conference, covering 24-week patient-reported cough outcomes in PH-ILD patients plus pharmacist care roles and caregiver mental health burdens. An encore session will feature safety and exploratory efficacy findings through Week 24.
1. PHA Conference Presentation
On June 11 at the PHA 2026 PH Conference in Dallas, Liquidia is slated to present four scientific posters from 4 to 5 p.m. CDT. The presentations will include new and encore data sessions, with posters immediately available online following the event.
2. ASCENT Cohort A Data Highlights
One poster (#1014) will detail 24-week patient-reported cough outcomes in pulmonary hypertension associated with interstitial lung disease (PH-ILD) from Cohort A of the ASCENT study. An encore presentation (#1060) will revisit safety and exploratory efficacy data on LIQ861 dry-powder treprostinil through Week 24.
3. Broader Research Themes
Additional posters will examine the evolving role of pharmacists within PH care teams (#1072) and assess the mental health burden on caregivers of PH patients (#1055). These studies underscore Liquidia’s focus on holistic patient and caregiver experiences in pulmonary hypertension management.
